Adenocarcinoma: all 1,996 studies
Page 2 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.
- Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric CancerNot yet recruitingNCT06871527Phase 1/2
- Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type AdenocarcinomaNot yet recruitingNCT06870565Phase 3
- A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1RecruitingNCT06867497Phase 1
- Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic AdenocarcinomaRecruitingNCT06867172
- Flotufolastat F 18 PET in Men With Very Low PSA RecurrenceRecruitingNCT06862856
- Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung AdenocarcinomaNot yet recruitingNCT06858410Phase 3
- Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma PatientsNot yet recruitingNCT06857786Phase 1
- Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.Not yet recruitingNCT06855589Phase 3
- Dose Escalated Radiotherapy for Rectal Cancers Using MR-guided RadiotherapyRecruitingNCT06854679Not applicable
- Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal AdenocarcinomaRecruitingNCT06846346Phase 2
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideRecruitingNCT06844383Phase 2
- Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer SurvivorsEnrolling by invitationNCT06834204Not applicable
- Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate CancerRecruitingNCT06834152
- EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCERRecruitingNCT06822036Not applicable
- Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II TrialRecruitingNCT06816914Phase 2
- The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT06807112
- Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical AdenocarcinomaNot yet recruitingNCT06805864Phase 2
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyRecruitingNCT06805812
- Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06801236Phase 1
- Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical StudyRecruitingNCT06794073Not applicable
- Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic CancerRecruitingNCT06789679Phase 2
- Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical StudyNot yet recruitingNCT06785584Phase 4
- Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer PatientsNot yet recruitingNCT06783153Phase 1/2
- Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic CancerRecruitingNCT06782932Phase 1/2
- Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor TypesRecruitingNCT06782412Phase 2/3
- Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor LesionsRecruitingNCT06774781
- A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRGRecruitingNCT06774222Phase 2
- BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06773312Phase 1
- Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06764251Phase 2
- Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant AscitesRecruitingNCT06759064Phase 1/2
- An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.Not yet recruitingNCT06753721Phase 1/2
- QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDACNot yet recruitingNCT06750861Phase 2
- EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial SarcomaNot yet recruitingNCT06748872Phase 1
- Lymph Node Pathologic Grading StrategyRecruitingNCT06745830
- The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic AdenocarcinomaRecruitingNCT06743867Phase 1
- Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant ChemoradiotherapyRecruitingNCT06687876Phase 2
- Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast CancerRecruitingNCT06671262Phase 2
- Hypoxia Driven Metabolic Response in Oesophagogastric AdenocarcinomaRecruitingNCT06669663
- SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal CancerNot yet recruitingNCT06666166Phase 2
- Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.RecruitingNCT06655233
- Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1RecruitingNCT06649474Not applicable
- Phase IIT Trial of SNA014Not yet recruitingNCT06646783Early Phase 1
- Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung AdenocarcinomaNot yet recruitingNCT06645743
- Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction AdenocarcinomaRecruitingNCT06644352Not applicable
- Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.RecruitingNCT06642857
- Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.RecruitingNCT06640166Phase 2
- Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate CancerRecruitingNCT06631521Phase 1
- Asian Watch-and-Wait Database (AWWD)RecruitingNCT06631443
- Innovative Therapeutic Treatments to Inhibit Perineural Invasion in Pancreatic AdenocarcinomaNot yet recruitingNCT06616688
- Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerRecruitingNCT06616597Phase 2
- Pan-tumor MRD StudyRecruitingNCT06605404
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseRecruitingNCT06592924Phase 3
- The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06587425Phase 2
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06577376Phase 1/2
- Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ PatiensRecruitingNCT06572319Phase 1/2
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06561685Phase 1
- HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological OutcomesRecruitingNCT06550063
- The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic CancerRecruitingNCT06497777
- Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction CancerRecruitingNCT06496789Phase 2
- Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesNot yet recruitingNCT06483672Phase 2
- Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility StudyRecruitingNCT06482788Phase 2
- AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
- Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric JunctionNot yet recruitingNCT06469060Phase 2
- NALIRIFOX as Induction Therapy in LAPCRecruitingNCT06467565Phase 2
- Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric CancerNot yet recruitingNCT06454435Phase 2
- Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT ParameterRecruitingNCT06441357
- Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant ChemotherapyRecruitingNCT06435767
- Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 GastrectomyNot yet recruitingNCT06419140Phase 2
- A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06415669Phase 2
- Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albuminRecruitingNCT06406426Phase 2
- NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingNCT06405490Phase 2
- Dissecting the Role of MIcrobioMe in gastroEsophageal Tumor: a multIdisCiplinary Longitudinal StudyRecruitingNCT06405035
- PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDACRecruitingNCT06396637Phase 2
- Namodenoson Treatment of Advanced Pancreatic CancerRecruitingNCT06387342Phase 2
- Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate CancerNot yet recruitingNCT06387238Not applicable
- Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor MicroenvironmentRecruitingNCT06387134Not applicable
- Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain MetastasesNot yet recruitingNCT06374888Phase 2
- Comparison of Outcomes of Multiple Platforms for Assisted Robotic - GastrectomyRecruitingNCT06362070Not applicable
- Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic CancerNot yet recruitingNCT06361030Phase 2
- Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06353152Phase 1
- A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.RecruitingNCT06349044Not applicable
- PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)Not yet recruitingNCT06345599Phase 1/2
- A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06341335Phase 3
- Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06321913Phase 2
- A Prospective Study on Esophagogastrostomy by an Innovative Surgical TechniqueRecruitingNCT06300879Not applicable
- Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer SurgeryRecruitingNCT06289374
- SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade DysplasiaRecruitingNCT06280690Phase 2
- SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)RecruitingNCT06278857Phase 2
- Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel AdenocarcinomaRecruitingNCT06278545Phase 2
- A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma PatientsRecruitingNCT06277024Not applicable
- The LINFU® U.S. Registry for the in the General Population Without Risk FactorsNot yet recruitingNCT06276803
- The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal AdenocarcinomaRecruitingNCT06266832Phase 2
- A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal AdenocarcinomaRecruitingNCT06261359Phase 2
- Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric JunctionRecruitingNCT06250894Phase 2
- Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical StudyNot yet recruitingNCT06241469Phase 2
- Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingNCT06222944Phase 2
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
- Multicenter Observational Study Taulí-T1 Classification for the Management of pT1 Rectal AdenocarcinomaRecruitingNCT06218108
- Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerRecruitingNCT06205836Phase 2
- Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast CancerRecruitingNCT06199895Phase 2